(603.19) Acute Impact of JUUL Electronic Cigarette use on Cerebral Vascular Vasodilator Responsiveness

Poster Board Number: E465

Jeremiah Campbell (University of Texas at Arlington), John Akins (University of Texas at Arlington), Danny Dabroy (University of Texas at Arlington), Farjana Yesmin (University of Texas at Arlington), Michael Nelson (University of Texas at Arlington), Ziyad Ben Taleb (University of Texas at Arlington), R. Matthew Brothers (University of Texas at Arlington)

Background: Cardiovascular disease is a major cause of death among cigarette smokers and is responsible for ~30% of heart disease related mortality in the U.S each year. Although cigarette smoking rates have declined in recent years, the use of electronic cigarettes (e-cigarettes) continues to gain popularity in the U.S. and have generated widespread debate within the public health community, mostly due to the lack of scientific evidence regarding their safety and impact on health and behavior. The increasing rates of e-cigarette use in the U.S have been largely attributed to the recent emergence of the high-nicotine-delivery pod-based devices such as JUUL. Unlike e-cigarettes, the literature surrounding the health impact of combustible cigarette smoking is well developed with overwhelming evidence of an adverse impact on various cardiovascular outcomes including impaired cerebral perfusion/vascular function. However, the impact of e-cigarettes on cerebral vascular function remains to be elucidated, representing a major knowledge gap and research priority. Hypothesis: This study tested the hypothesis that acute e-cigarette vaping (JUUL) will impair cerebral vascular function as indexed by the cerebral vasodilatory responsiveness to a hypercapnic stimulus.

Methods:  A total of 16 adult smokers (mean age=25±5 yrs.) participated in this pilot study which occurred following an overnight fast. Cerebral vascular function was assessed as the hyperemic response to rebreathing-induced hypercapnia before and ~45 min following a vaping session (10 puffs; 3s each, separated by 30s intervals). Heart rate (ECG), respiration (Pneumotrace), beat-to-beat blood pressure (Finometer), middle cerebral artery mean blood velocity (MCAv - transcranial Doppler) and breath-by-breath end-tidal carbon dioxide concentration (PETCO2 - capnograph) were continuously measured. Cerebral vascular conductance index (CVCi) was calculated as MCAv / mean arterial pressure. Cerebral vasodilatory responsiveness was assessed as % increase in CVCi (%CVCi) during the highest common magnitude of hypercapnia achieved during the pre- and post-vaping trials.

Results: All CVCi data are reported at the highest common magnitude of hypercapnia achieved during the pre- and post-vaping sessions (ΔPETCO2 Pre: 13±2 mmHg, ΔPETCO2 Post: 12±2 mmHg; P=0.11). Cerebral vascular function/vasodilatory responsiveness, as assessed by the CVCi response to the hypercapnic challenge was significantly blunted following the vaping session (Pre: +52±25%, Post: +42±14%; P=0.04).

Conclusions:  Our preliminary results suggest that e-cigarette vaping using JUUL acutely impairs cerebral vascular function as indexed by cerebral vasodilatory responsiveness to a hypercapnic challenge. These findings highlight the need for longitudinal studies to assess the long-term impact of JUUL use on cerebral vascular function as well as other indices of cardiovascular health.

Institutional Start-up funds Provided by the University of Texas at Arlington / The College of Nursing and Health Innovation